<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Mem Inst Oswaldo Cruz</journal-id>
      <journal-id journal-id-type="iso-abbrev">Mem. Inst. Oswaldo Cruz</journal-id>
      <journal-title-group>
        <journal-title>Mem&#xF3;rias do Instituto Oswaldo Cruz</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0074-0276</issn>
      <issn pub-type="epub">1678-8060</issn>
      <publisher>
        <publisher-name>Instituto Oswaldo Cruz, Minist&#xE9;rio da Sa&#xFA;de</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24714965</article-id>
      <article-id pub-id-type="pmc">4015255</article-id>
      <article-id pub-id-type="publisher-id">0074-02760130312</article-id>
      <article-id pub-id-type="doi">10.1590/0074-02760130312</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clinical features and laboratory findings of human
parvovirus B19 in human immunodeficiency virus-infected patients</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira</surname>
            <given-names>Renata Freire Alves</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Garcia</surname>
            <given-names>Rita de C&#xE1;ssia Nasser Cubel</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Azevedo</surname>
            <given-names>K&#xE1;tia Martins Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Set&#xFA;bal</surname>
            <given-names>S&#xE9;rgio</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Siqueira</surname>
            <given-names>Marilda Agudo Mendon&#xE7;a Teixeira</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Solange Artimos</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">3</xref>
          <xref ref-type="corresp" rid="c01">+</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> Programa de P&#xF3;s-Gradua&#xE7;&#xE3;o em Ci&#xEA;ncias M&#xE9;dicas, Faculdade de Medicina,
Universidade Federal Fluminense, Niter&#xF3;i, RJ, <country>Brasil</country></aff>
      <aff id="aff2"><label>3</label> Disciplina de Doen&#xE7;as Infecciosas e Parasit&#xE1;rias, Faculdade de
Medicina, Universidade Federal Fluminense, Niter&#xF3;i, RJ, <country>Brasil</country></aff>
      <aff id="aff3"><label>2</label> Departamento de Microbiologia e Parasitologia, Instituto Biom&#xE9;dico,
Universidade Federal Fluminense, Niter&#xF3;i, RJ, <country>Brasil</country></aff>
      <aff id="aff4"><label>4</label> Laborat&#xF3;rio de V&#xED;rus Respirat&#xF3;rios e Sarampo, Instituto Oswaldo
Cruz-Fiocruz, Rio de Janeiro, RJ, <country>Brasil</country></aff>
      <author-notes>
        <corresp id="c01"><label>+</label> Corresponding author: <email>artimos@vm.uff.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2014</year>
      </pub-date>
      <volume>109</volume>
      <issue>2</issue>
      <fpage>168</fpage>
      <lpage>173</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>6</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Immunocompromised patients may develop severe chronic anaemia when infected by human
parvovirus B19 (B19V). However, this is not the case in human immunodeficiency virus
(HIV)-infected patients with good adherence to highly active antiretroviral treatment
(HAART). In this study, we investigated the clinical evolution of five HIV-infected
patients receiving HAART who had B19V infections confirmed by serum polymerase chain
reaction. Four of the patients were infected with genotype 1a strains and the
remaining patient was infected with a genotype 3b strain. Anaemia was detected in
three of the patients, but all patients recovered without requiring immunoglobulin
and/or blood transfusions. In all cases, the attending physicians did not suspect the
B19V infections. There was no apparent relationship between the infecting genotype
and the clinical course. In the HAART era, B19V infections in HIV-positive patients
may be limited, subtle or unapparent.</p>
      </abstract>
      <kwd-group>
        <kwd>HIV</kwd>
        <kwd>human parvovirus B19</kwd>
        <kwd>seroconversion</kwd>
      </kwd-group>
      <funding-group>
        <funding-statement>Financial support: CNPq (473432/2010-20)</funding-statement>
      </funding-group>
      <counts>
        <table-count count="5"/>
        <ref-count count="34"/>
        <page-count count="6"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p>Parvovirus B19 (B19V), a member of the genus <italic>Erythrovirus</italic> within the
Parvoviridae family, has been grouped into three distinct genotypes: (i) genotype 1, with
subtypes 1a (the prototypic virus) and 1b, (ii) genotype 2 (A6 and LaLi strains) and (iii)
genotype 3, with subtypes 3a (V9 strains) and 3b (D91.1 strains) (<xref rid="B22" ref-type="bibr">Nguyen et al. 1999</xref>, <xref rid="B23" ref-type="bibr">2002</xref>, <xref rid="B28" ref-type="bibr">Servant et al. 2002</xref>, <xref rid="B7" ref-type="bibr">Fauquet et al. 2005</xref>).</p>
    <p>B19V primarily infects erythroid cells, leading to transient inhibition of erythropoiesis.
In immunocompetent individuals, it usually causes an acute and self-limited childhood
disease known as erythema infectiosum (EI) (&#x201C;slapped cheek&#x201D; rash or 5th disease). Adults
with EI (particularly females) frequently present with joint symptoms. However, most
patients are asymptomatic (<xref rid="B34" ref-type="bibr">Woolf et al. 1989</xref>).
Immunocompromised patients who are unable to produce neutralising antibodies may develop
severe chronic anaemia. In human immunodeficiency virus (HIV)-infected patients with
residual immunity, the clinical manifestations, if any, are those of fifth disease (<xref rid="B10" ref-type="bibr">Frickhofen &amp; Young 1990</xref>). With the advent of highly
active antiretroviral treatment (HAART), several studies, including one from our group
(<xref rid="B4" ref-type="bibr">de Azevedo et al. 2012</xref>), have shown a decrease in
cases of anaemia caused by B19V (<xref rid="B21" ref-type="bibr">Mylonakis et al.
1999</xref>, <xref rid="B31" ref-type="bibr">Ware &amp; Moore 2001</xref>).</p>
    <p>To better understand the importance of B19V infection in the HAART era, a study to estimate
the frequency of B19V seroconversion in a cohort of HIV-infected patients was conducted by
our group during an eight-year period (2001-2008) at the Infectious Diseases Department of
Antonio Pedro University Hospital (HUAP) at the Fluminense Federal University (Niter&#xF3;i,
state of Rio de Janeiro, Brazil) (<xref rid="B5" ref-type="bibr">de Azevedo et al.
2009</xref>). Seroconversions were detected in approximately 30% (28 of 88) of our
anti-B19 IgG-negative patients, a similar proportion to that found by others (<xref rid="B3" ref-type="bibr">Chernak et al. 1995</xref>, <xref rid="B21" ref-type="bibr">Mylonakis et al. 1999</xref>). Most seroconversions occurred during incidence peaks of
a B19V infection in Niter&#xF3;i (<xref rid="B24" ref-type="bibr">Oliveira et al. 2005</xref>,
<xref rid="B4" ref-type="bibr">de Azevedo et al. 2012</xref>). All sera from the 88
patients were tested by polymerase chain reactions (PCRs) and B19 DNA was detected in five
of the patients, four of whom also exhibited seroconversion. This paper describes the
clinical and laboratory findings of B19V infections in these five HIV-infected
patients.</p>
    <sec>
      <title>PATIENTS, MATERIALS AND METHODS</title>
      <p>Data, such as haemoglobin (Hb) concentration, CD4<sup>+</sup> T cell counts and B19V IgG
and IgM serology, were retrieved from a previous study by our group (<xref rid="B4" ref-type="bibr">de Azevedo et al. 2012</xref>). ELISAs (Biotrin
International<sup>TM</sup>, Dublin, Ireland) were performed, according to the
manufacturer&#x2019;s instructions, to detect IgG and IgM antibodies to B19 in all sera. The
following definitions were used in this study: (i) anaemia was defined according to the
World Health Organization (WHO 2001) criteria as a Hb concentration below 13 g/dL in men
and below 12 g/dL in women and (ii) severe anaemia was defined as a Hb concentration
below 7 g/dL.</p>
      <p>PCRs were performed to detect and genotype B19V. Briefly, viral DNA was extracted from
serum samples of 88 HIV-positive patients using a QIAamp DNA Blood Mini Kit (QIAGEN,
Hilden, Germany) according to the manufacturer&#x2019;s instructions. For the screening of B19V
DNA, PCR was performed using the primers E1905F (nt 1905-1923) and E1987R (nt
2007-1987), which amplify a 102-bp fragment of the NS1 gene as previously described by
<xref rid="B23" ref-type="bibr">Nguyen et al. (2002)</xref>, with some modifications
(<xref rid="B4" ref-type="bibr">de Azevedo et al. 2012</xref>). This PCR can
routinely detect as few as 20 copies of the B19V DNA (Nguyen et al. 2012).</p>
      <p>To genotype the B19V strains detected in HIV-positive patients, a semi-nested PCR using
the primer pairs P12/P16 (4127-4689) and P13/P16 (4214-4689) for partial amplification
of the VP1/VP2 capsid gene was performed as described by <xref rid="B6" ref-type="bibr">Durigon et al. (1993)</xref>. The 476-bp amplicons were purified using
GFX<sup>TM</sup> PCR DNA and the Gel Band Purification kit (GE, Healthcare, UK) and
were then subjected to direct sequencing using the BigDye terminator v. 1.1 cycle
sequencing kit (Applied Biosystems, CA, USA) (<xref rid="B25" ref-type="bibr">Otto et
al. 2008</xref>).</p>
      <p>Sequences were retrieved and analysed by the Bio-Edit sequence alignment editor, v.
7.0.1 (mbio.ncsu.edu/BioEdit/bioedit.html) and they were compared with the following
sequences available in GenBank (<xref rid="B14" ref-type="bibr">Hall 1999</xref>):
genotype 1a: M24682-Wi (UK); genotype 1b: DQ35706 and DQ35705 (Ghana); genotype 2:
AY06477-A6 (Denmark) and AY04416-LaLi; genotype 3a: NC0049-V9 (Italy); genotype 3b:
Z68146 (UK), AF162273 (Italy), AY083234-D01.1 (France), DQ234778, DQ234779.2 (Ghana),
EF089227, EF089229.1 (Brazil/PA) and AY647977.1 (Brazil/SP).</p>
      <p>
<italic>Ethics - </italic>Written informed consent was obtained from all volunteers and
the project was approved by the Hospital Review Board (CMM/HUAP 134/05).</p>
    </sec>
    <sec sec-type="results">
      <title>RESULTS</title>
      <p>
<italic>Case 1 </italic>- A male patient diagnosed with acquired immune deficiency
syndrome (AIDS) in 1996 at 41 years of age, with poor adherence to HAART. The
observation period started in December 2001 (CD4<sup>+</sup> T cell count: 158
cells/mm<sup>3</sup>; anti B19V IgG: negative). There was a gradual decrease in
CD4<sup>+</sup> T cell counts, which reached 3 cells/mm<sup>3</sup> in August 2004.
In February 2005, the patient was hospitalised because of fever, hepatosplenomegaly,
severe anaemia (Hb: 5.9 g/dL) and multiple opportunistic infections (oro-oesophageal
candidiasis, perianal condylomata and herpes). The patient underwent a bone marrow
biopsy (February 2005) and was started on empirical treatment for atypical
mycobacteriosis. Clinical improvement was observed and the patient did well afterward,
which was attributed to a better adherence to HAART (lamivudine, stavudine, efavirenz
and lopinavir/ritonavir). The biopsy report described <italic>&#x201C;</italic>overall
cellularity of 60%, with presence of the three series. The myeloid/erythroid ratio was
2:1, with predominance of immature forms, numerous myeloblasts and moderate increase in
the number of red blood cells with megaloblastic maturation. Megakaryocytes were
observed in the usual number, but with frequent atypical forms. There were rare
erythroblasts with nuclear viral inclusions consistent with B19V. Conclusion:
myelodysplastic changes secondary to HIV infection, compatible with B19V
infection&#x201D;<italic>.</italic> The patient received neither immunoglobulin therapy nor
a blood transfusion. There was a gradual recovery from anaemia during 2005. In November
2005, stavudine was replaced by zidovudine to improve adherence. In December 2005,
seroconversion (anti-B19V IgG-positive and anti-B19V IgM-positive) and the presence of
B19V DNA (strain RJ 011/2005, genotype 1a) were both detected in association with an
increase in the CD4<sup>+</sup> T cell count (34 cells/mm<sup>3</sup>) and resolution of
anaemia (Hb: 13.9 g/dL) (<xref ref-type="table" rid="t01">Table I</xref>). A subsequent
serum sample (June 2006) was negative for B19V DNA.</p>
      <p>
<table-wrap id="t01" orientation="portrait" position="float"><label>TABLE I</label><caption><title> - Laboratory data of Case 1</title></caption><table frame="hsides" rules="groups"><colgroup width="7%" span="1"><col width="10%" span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"> Month/year </th><th rowspan="1" colspan="1"> Dec/2001 </th><th rowspan="1" colspan="1"> Mar/2002 </th><th rowspan="1" colspan="1"> Aug/2002 </th><th rowspan="1" colspan="1"> Jul/2003 </th><th rowspan="1" colspan="1"> Feb/2004 </th><th rowspan="1" colspan="1"> Aug/2004 </th><th rowspan="1" colspan="1"> Feb/2005 </th><th rowspan="1" colspan="1"> Mar/2005 </th><th rowspan="1" colspan="1"> Jul/2005 </th><th rowspan="1" colspan="1"> Sep/2005 </th><th rowspan="1" colspan="1"> Dec/2005 </th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> IgG anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> IgM anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> PCR-B19 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> CD4<sup>+</sup> (cells/mm<sup>3</sup>) </td><td align="center" rowspan="1" colspan="1"> 158 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 118 </td><td align="center" rowspan="1" colspan="1"> 45 </td><td align="center" rowspan="1" colspan="1"> 9 </td><td align="center" rowspan="1" colspan="1"> 3 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 1 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 34 </td></tr><tr><td rowspan="1" colspan="1"> Hb (g/dL) </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 13.1 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 5.9 </td><td align="center" rowspan="1" colspan="1"> 6.9 </td><td align="center" rowspan="1" colspan="1"> 10 </td><td align="center" rowspan="1" colspan="1"> 10.5 </td><td align="center" rowspan="1" colspan="1"> 13.9 </td></tr></tbody></table><table-wrap-foot><fn id="TFN01t01"><p>B19V: parvovirus B19; Hb: haemoglobin; NEG: negative; PCR: polymerase chain
reaction; POS: positive; -: lack of data in the medical records.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>
<italic>Case 2 </italic>- A female patient diagnosed with AIDS in 1997 at 54 years of
age, when she was started on HAART with good adherence to therapy and immune recovery.
The observation period began in December 2001 (CD4<sup>+ </sup>T cell count: 598
cells/mm<sup>3</sup>). Seroconversion to B19V (anti-B19 IgG) was observed in June
2005. There is no record of blood counts during the period of seroconversion (November
2004-June 2005). During this period, there were no complaints or changes in physical
examination suggestive of anaemia. A serum sample collected in June 2005 (strain RJ
026/2005, genotype 1a) was B19V DNA-positive by PCR. The next available blood sample
(September 2005) remained B19V DNA-positive (<xref ref-type="table" rid="t02">Table
II</xref>), but the subsequent sample (January 2006) was negative for B19V DNA.</p>
      <p>
<table-wrap id="t02" orientation="portrait" position="float"><label>TABLE II</label><caption><title> - Laboratory data of Case 2</title></caption><table frame="hsides" rules="groups"><colgroup width="7%" span="1"><col width="10%" span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"> Month/year </th><th rowspan="1" colspan="1"> Dec/2001 </th><th rowspan="1" colspan="1"> May/2002 </th><th rowspan="1" colspan="1"> Oct/2002 </th><th rowspan="1" colspan="1"> Oct/2003 </th><th rowspan="1" colspan="1"> Jun/2003 </th><th rowspan="1" colspan="1"> Jul/2004 </th><th rowspan="1" colspan="1"> Nov/2004 </th><th rowspan="1" colspan="1"> Jun/2005 </th><th rowspan="1" colspan="1"> Sep/2005 </th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> IgG anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> IgM anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td></tr><tr><td rowspan="1" colspan="1"> PCR-B19 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> CD4<sup>+</sup> (cells/mm<sup>3</sup>) </td><td align="center" rowspan="1" colspan="1"> 589 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 241 </td><td align="center" rowspan="1" colspan="1"> 474 </td><td align="center" rowspan="1" colspan="1"> 702 </td><td align="center" rowspan="1" colspan="1"> 712 </td><td align="center" rowspan="1" colspan="1"> 769 </td><td align="center" rowspan="1" colspan="1"> 613 </td><td align="center" rowspan="1" colspan="1"> 702 </td></tr><tr><td rowspan="1" colspan="1"> Hb (g/dL) </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 12.6 </td><td align="center" rowspan="1" colspan="1"> 13.5 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 13 </td></tr></tbody></table><table-wrap-foot><fn id="TFN01t02"><p>B19V: parvovirus B19; Hb: haemoglobin; NEG: negative; PCR: polymerase chain
reaction; POS: positive; -: lack of data in the medical records.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>
<italic>Case 3 </italic>- A woman diagnosed with AIDS in 1996 at 36 years of age, when
she was started on HAART, followed by immunological recovery. The observation period
began in January 2002 (CD4<sup>+</sup> T count: 520 cells/mm<sup>3</sup>). B19V
seroconversion (anti-B19 IgM and anti-B19 IgG) was observed in September 2005
(CD4<sup>+</sup> T count: 649 cells/mm<sup>3</sup>). At that time, there were no
complaints or physical examination changes suggestive of anaemia. A serum sample
collected in September 2005 (strain RJ 071/2005, genotype 3b) was B19V DNA-positive
(<xref ref-type="table" rid="t03">Table III</xref>). Two subsequent samples collected
in June 2006 and September 2006 were, respectively, positive and negative for B19V
DNA.</p>
      <p>
<table-wrap id="t03" orientation="portrait" position="float"><label>TABLE III</label><caption><title> - Laboratory data of Case 3</title></caption><table frame="hsides" rules="groups"><colgroup width="10%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"> Month/year </th><th rowspan="1" colspan="1"> Jan/2002 </th><th rowspan="1" colspan="1"> Oct/2002 </th><th rowspan="1" colspan="1"> Dec/2002 </th><th rowspan="1" colspan="1"> Apr/2003 </th><th rowspan="1" colspan="1"> Sep/2003 </th><th rowspan="1" colspan="1"> May/2004 </th><th rowspan="1" colspan="1"> Aug/2004 </th><th rowspan="1" colspan="1"> Feb/2005 </th><th rowspan="1" colspan="1"> Sep/2005 </th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> IgG anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> IgM anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> PCR-B19 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> CD4<sup>+</sup> (cells/mm<sup>3</sup>) </td><td align="center" rowspan="1" colspan="1"> 520 </td><td align="center" rowspan="1" colspan="1"> 681 </td><td rowspan="1" colspan="1">&#xA0;</td><td rowspan="1" colspan="1">&#xA0;</td><td rowspan="1" colspan="1">&#xA0;</td><td rowspan="1" colspan="1">&#xA0;</td><td align="center" rowspan="1" colspan="1"> 483 </td><td align="center" rowspan="1" colspan="1"> 610 </td><td align="center" rowspan="1" colspan="1"> 649 </td></tr><tr><td rowspan="1" colspan="1"> Hb (g/dL) </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 13.7 </td><td align="center" rowspan="1" colspan="1"> 13.2 </td><td align="center" rowspan="1" colspan="1"> 13.9 </td><td align="center" rowspan="1" colspan="1"> 13.1 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td></tr></tbody></table><table-wrap-foot><fn id="TFN01t03"><p>B19V: parvovirus B19; Hb: haemoglobin; NEG: negative; PCR: polymerase chain
reaction; POS: positive; -: lack of data in the medical records.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>
<italic>Case 4 </italic>- A man diagnosed with AIDS in November 2003 at 33 years of age.
At that time, he presented with mild anaemia (Hb = 12.8 g/dL) attributed to HIV
infection. He began HAART in September 2004. The observation period started in November
2003 (CD4<sup>+</sup> T cell count: 215 cells/mm<sup>3</sup>). B19V seroconversion
(anti-B19 IgG) was observed in April 2007 (CD4<sup>+</sup> T cell count: 504
cells/mm<sup>3</sup>). Hb levels below 13.0 g/dL, suggestive of mild anaemia, were
observed from November 2003-July 2006, before the period of seroconversion (anti-B19
IgG) (July 2006-April 2007). A sample collected in July 2006 (strain RJ 350/2006,
genotype 1a) was B19V DNA-positive (<xref ref-type="table" rid="t04">Table IV</xref>). A
subsequent sample (April 2007) was negative for B19V DNA.</p>
      <p>
<table-wrap id="t04" orientation="portrait" position="float"><label>TABLE IV</label><caption><title> - Laboratory data of Case 4</title></caption><table frame="hsides" rules="groups"><colgroup width="13%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"> Month/year </th><th rowspan="1" colspan="1"> Nov/2003 </th><th rowspan="1" colspan="1"> Jan/2006 </th><th rowspan="1" colspan="1"> Jul/2006 </th><th rowspan="1" colspan="1"> Apr/2007 </th><th rowspan="1" colspan="1"> Jan/2008 </th><th rowspan="1" colspan="1"> Mar/2008 </th><th rowspan="1" colspan="1"> Jul/2008 </th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> IgG anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td><td align="center" rowspan="1" colspan="1"> POS </td><td align="center" rowspan="1" colspan="1"> POS </td><td align="center" rowspan="1" colspan="1"> POS </td></tr><tr><td rowspan="1" colspan="1"> IgM anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td></tr><tr><td rowspan="1" colspan="1"> PCR-B19 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td></tr><tr><td rowspan="1" colspan="1"> CD4<sup>+</sup> (cells/mm<sup>3</sup>) </td><td align="center" rowspan="1" colspan="1"> 215 </td><td align="center" rowspan="1" colspan="1"> 364 </td><td align="center" rowspan="1" colspan="1"> 327 </td><td align="center" rowspan="1" colspan="1"> 504 </td><td align="center" rowspan="1" colspan="1"> 539 </td><td align="center" rowspan="1" colspan="1"> 285 </td><td align="center" rowspan="1" colspan="1"> 528 </td></tr><tr><td rowspan="1" colspan="1"> Hb (g/dL) </td><td align="center" rowspan="1" colspan="1"> 12.8 </td><td align="center" rowspan="1" colspan="1"> 12.3 </td><td align="center" rowspan="1" colspan="1"> 12.5 </td><td align="center" rowspan="1" colspan="1"> 14.2 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 13.9 </td><td align="center" rowspan="1" colspan="1"> 13.6 </td></tr></tbody></table><table-wrap-foot><fn id="TFN01t04"><p>B19V: parvovirus B19; Hb: haemoglobin; NEG: negative; PCR: polymerase chain
reaction; POS: positive; -: lack of data in the medical records.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>
<italic>Case 5 </italic>- A man diagnosed with AIDS in November 2001 at 35 years of age.
The observation period began in January 2002 (CD4<sup>+</sup> T cell count: 80
cells/mm<sup>3</sup>), when HAART (zidovudine, lamivudine and efavirenz) was started
and it ended in October 2005 (CD4<sup>+</sup> T cell count: 244 cells/mm<sup>3</sup>).
The patient had several opportunistic infections and anaemia during the follow-up and a
decrease in Hb level (5.9 g/dL) was observed in June 2002. In addition, CD4<sup>+</sup>
T cell counts less than 100 cells/mm<sup>3</sup> were observed until November 2002. As
the first test for the presence of IgG antibodies was indeterminate or weakly positive,
these samples were tested again and found to be negative. Nevertheless, B19 DNA was
detected in one of the samples (November 2002, strain RJ 109/2002, genotype 1a). At this
time, the Hb level was 9.14 g/dL and, thus, no longer compatible with severe anaemia
(<xref ref-type="table" rid="t05">Table V</xref>). There is no record of a B19V
outbreak during 2002/2003 (<xref rid="B24" ref-type="bibr">Oliveira et al.
2005</xref>).</p>
      <p>
<table-wrap id="t05" orientation="portrait" position="float"><label>TABLE V</label><caption><title> - Laboratory data of Case 5</title></caption><table frame="hsides" rules="groups"><colgroup width="13%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"> Month/year </th><th rowspan="1" colspan="1"> Jan/2002 </th><th rowspan="1" colspan="1"> Jun/2002 </th><th rowspan="1" colspan="1"> Nov/2002 </th><th rowspan="1" colspan="1"> Jun/2003 </th><th rowspan="1" colspan="1"> Jul/2004 </th><th rowspan="1" colspan="1"> May/2005 </th><th rowspan="1" colspan="1"> Oct/2005 </th></tr></thead><tbody><tr><td rowspan="1" colspan="1"> Test 1 IgG anti-B19V </td><td align="center" rowspan="1" colspan="1"> IND </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> +/-<sup><italic>a</italic></sup>
</td><td align="center" rowspan="1" colspan="1"> IND </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> IND </td><td align="center" rowspan="1" colspan="1"> IND </td></tr><tr><td rowspan="1" colspan="1"> Test 2 IgG antiB19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td></tr><tr><td rowspan="1" colspan="1"> Test 3 IgG anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td></tr><tr><td rowspan="1" colspan="1"> IgM anti-B19V </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> NEG </td></tr><tr><td rowspan="1" colspan="1"> PCR-B19 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> POS </td><td align="center" rowspan="1" colspan="1"> NEG </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> - </td></tr><tr><td rowspan="1" colspan="1"> CD4<sup>+</sup> (cells/mm<sup>3</sup>) </td><td align="center" rowspan="1" colspan="1"> 80 </td><td align="center" rowspan="1" colspan="1"> 61 </td><td align="center" rowspan="1" colspan="1"> 36 </td><td align="center" rowspan="1" colspan="1"> 314 </td><td align="center" rowspan="1" colspan="1"> 253 </td><td align="center" rowspan="1" colspan="1"> 344 </td><td align="center" rowspan="1" colspan="1"> 244 </td></tr><tr><td rowspan="1" colspan="1"> Hb (g/dL) </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 5.92 </td><td align="center" rowspan="1" colspan="1"> 9.14 </td><td align="center" rowspan="1" colspan="1"> 11.3 </td><td align="center" rowspan="1" colspan="1"> 12.3 </td><td align="center" rowspan="1" colspan="1"> - </td><td align="center" rowspan="1" colspan="1"> 13.7 </td></tr></tbody></table><table-wrap-foot><fn id="TFN01t05"><p>
<italic>a</italic>: weakly positive; B19V: parvovirus B19; Hb: haemoglobin;
IND: indetermined; NEG: negative; PCR: polymerase chain reaction; POS:
positive; -: lack of data in the medical records.</p></fn></table-wrap-foot></table-wrap>
</p>
      <p>According to sequence analysis of the VP1/VP2 capsid region, the strains RJ 011/2005, RJ
026/2005, RJ 109/2002 and RJ 350/2006 shared high nucleotide (nt) identity (100-99%)
with 1a B19V isolates from other countries (EU78564, M2468, M13178, EU478541, EU14278
and JN211184). One strain (RJ 071/2005) displayed 99.3-97.2% nt identity with 3b B19V
Brazilian isolates (EF089227 and EF089229). Based on their nt identity with other B19V
isolates previously described, four of the B19V strains in this study were characterised
as belonging to genotype 1a and one B19V strain was characterised as belonging to
genotype 3b.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>This is the first study to analyse clinical manifestations in HIV-infected patients
during an outbreak of B19V in Brazil. Persistent B19 infection has been reported to be
associated with HIV infection, possibly due to inability to mount a protective
B19-specific antibody response (<xref rid="B3" ref-type="bibr">Chernak et al.
1995</xref>, <xref rid="B30" ref-type="bibr">van Elsacker-Niele et al. 1996</xref>)
and some reports have shown that complete remission of B19-associated pure red cell
aplasia can be achieved just by treating patients with HAART (<xref rid="B21" ref-type="bibr">Mylonakis et al. 1999</xref>, <xref rid="B31" ref-type="bibr">Ware &amp;
Moore 2001</xref>).</p>
      <p>Our findings show that the impact of restoring the immune response by either starting or
continuing HAART may explain the reduction and even the elimination, of severe
haematological changes caused by B19V infections, even before a detectable increase in
the number of CD4<sup>+</sup> T cells in the blood occurs (Cases 1, 4 and 5). Although
anaemia had been detected in three patients (2 of whom had severe anaemia), all of the
patients recovered and none required immunoglobulin and/or blood transfusions, including
the two patients for whom no data existed in the medical records regarding the
occurrence of anaemia. Additionally, our results also show that B19 infection may be
apparent only in retrospective analyses, as there are many causes of anaemia in
HIV-infected patients, including co-infection by mycobacteria, fungus or
cytomegalovirus, adverse drug effects, lymphoma or the direct effect of HIV infection
itself on the bone marrow (<xref rid="B1" ref-type="bibr">Abkowitz et al. 1997</xref>,
<xref rid="B17" ref-type="bibr">Koduri 2000</xref>). As there are usually no clinical
clues of a B19V infection in these patients, the presence of anaemia, especially during
B19V epidemics, should alert the physician to the possibility of B19 infection.</p>
      <p>One of our patients (Case 3) had viraemia persisting for at least nine months (from
September 2005-June 2006). This propensity to develop protracted B19V viraemias in
HIV-infected and other immunosuppressed individuals was described long ago (<xref rid="B19" ref-type="bibr">Kurtzman et al. 1989b</xref>, <xref rid="B32" ref-type="bibr">Weiland et al. 1989</xref>, <xref rid="B11" ref-type="bibr">Frickhofen et
al. 1990</xref>, <xref rid="B13" ref-type="bibr">Gyllensten et al. 1994</xref>).
Prolonged viraemias have also been described in healthy blood donors (<xref rid="B15" ref-type="bibr">Hitzler &amp; Runkel 2002</xref>).</p>
      <p>Dissociation between the serological and molecular markers was observed in Case 5, most
likely due to the inability of this immunocompromised patient to produce neutralising
antibodies. According to <xref rid="B18" ref-type="bibr">Kurtzman et al. (1989a)</xref>,
the immune response may be quantitatively and qualitatively altered by immunosuppression
or during persistent infections. Consequently, in this clinical context, diagnostic
genome detection has been advocated by some authors (<xref rid="B2" ref-type="bibr">Calvet et al. 1999</xref>).</p>
      <p>It is well known that genotype 1 is the most common B19V genotype detected world-wide
(<xref rid="B29" ref-type="bibr">Servant-Delmas et al. 2010</xref>). In this study,
genotype 1 was detected in four of the five HIV-infected patients. This genotype was
also detected in EI patients during outbreaks in Niter&#xF3;i (<xref rid="B26" ref-type="bibr">Pereira et al. 2010</xref>). Unexpectedly, a genotype 3b strain was
detected in a sample from September 2005.</p>
      <p>
<xref rid="B8" ref-type="bibr">Ferry et al. (2009)</xref> found that the detection of
B19V genotype 2 or 3 DNA was infrequent in the blood samples of a large cohort of
immunocompromised, HIV-infected anaemic patients, despite the use of highly sensitive
real-time PCR methods. All three genotypes have been identified in Brazil, although
genotype 1 is the most common (<xref rid="B27" ref-type="bibr">Sanabani et al.
2006</xref>, <xref rid="B9" ref-type="bibr">Freitas et al. 2008</xref>, <xref rid="B16" ref-type="bibr">Keller et al. 2009</xref>, <xref rid="B12" ref-type="bibr">Garcia 2010</xref>). Genotype 3b was identified in a serum sample obtained from a
patient with systemic lupus erythematosus in 1999 in Bel&#xE9;m, state of Par&#xE1; (<xref rid="B9" ref-type="bibr">Freitas et al. 2008</xref>); in a sample from a patient from
S&#xE3;o Paulo, state of S&#xE3;o Paulo, with anaemia after a kidney transplantation in 2004
(<xref rid="B16" ref-type="bibr">Keller et al. 2009</xref>) and in children with
exanthaematic disease (<xref rid="B9" ref-type="bibr">Freitas et al. 2008</xref>).</p>
      <p>This study had the limitations inherent in retrospective studies involving the review of
medical records. One such limitation was the long interval between blood collections.
These long intervals made it difficult to precisely know the time of B19V seroconversion
and they prevented complete analysis of the interactions between serological (especially
IgM) and molecular markers. Another limitation was not performing quantitative PCR
(qPCR), as it is known that the virus may persist for a long time and maintain
persistent viraemias in HIV-positive patients (<xref rid="B11" ref-type="bibr">Frickhofen et al. 1990</xref>, <xref rid="B20" ref-type="bibr">Miao et al.
2012</xref>). However, the following evidence of primary infections in our patients
was found: (i) the previous serum samples (in relation to the PCR-positive samples) were
negative by PCR, (ii) the subsequent samples (in relation to the PCR-positive samples)
were also negative by PCR, (iii) seroconversions were observed in four of the five cases
and (iv) all but one case occurred during an outbreak of B19V infection in Niter&#xF3;i. If
these positive PCRs corresponded to long persistent infections in HIV-positive patients
who were recovering their immunity, a decrease in the intensity of the viraemia would be
expected by the time of seroconversion, together with a switch from positive to negative
PCR results. This outcome did not occur, as the PCR results changed from negative to
positive at the time of seroconversion and then changed from positive to negative
afterward. Considering the high sensitivity of qPCR and the long intervals between the
blood collections, the use of this technique would be expected to detect low DNA levels
in the blood samples despite the presence of circulating IgG antibodies. However, this
finding would not change the interpretation of the obtained results.</p>
      <p>In conclusion, our findings show that B19V infections in HIV-infected patients may be
limited, subtle and apparent only in retrospective analyses due to the variety of causes
of anaemia in these patients and the adequate use of HAART. The finding of four strains
of genotype 1 and one strain of genotype 3 is consistent with their relative frequency
in Brazil. There were no apparent relationships between the infecting genotype and the
clinical course.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGEMENTS</title>
      <p>To Dr Jussara P Nascimento (<italic>in memoriam</italic>), from UFF, for providing human
parvovirus tests, and to the general practitioners from the Department of Infectious
Diseases/HUAP, for clinical support.</p>
    </ack>
    <fn-group>
      <fn id="fn1" fn-type="financial-disclosure">
        <p>Financial support: CNPq (473432/2010-20)</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B1">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Abkowitz</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Kovach</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <year>1997</year>
          <article-title>Clinical relevance of parvovirus B19 as a cause of
anaemia in patients with human immunodeficiency virus infection</article-title>
          <source>J Infect Dis</source>
          <volume>176</volume>
          <fpage>269</fpage>
          <lpage>273</lpage>
          <pub-id pub-id-type="pmid">9207380</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Calvet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pujol</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Bertocchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bastien</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Boissonnat</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mornex</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <year>1999</year>
          <article-title>Parvovirus B19 infection in thoracic organ transplant
recipients</article-title>
          <source>J Clin Virol</source>
          <volume>13</volume>
          <fpage>37</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">10405890</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Chernak</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dubin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Naides</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Hodinka</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>MacGregor</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <year>1995</year>
          <article-title>Infection due to parvovirus B19 in patients infected
with human immunodeficiency virus</article-title>
          <source>Clin Infect Dis</source>
          <volume>20</volume>
          <elocation-id/>
        </element-citation>
      </ref>
      <ref id="B4">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>de Azevedo</surname>
              <given-names>KML</given-names>
            </name>
            <name>
              <surname>Set&#xFA;bal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>LAB</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>RCNC</given-names>
            </name>
            <name>
              <surname>Siqueira</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>RFA</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <year>2012</year>
          <article-title>Parvovirus B19 seroconversion in a cohort of human
immunodeficiency virus-infected patients</article-title>
          <source>Mem Inst Oswaldo Cruz</source>
          <volume>107</volume>
          <fpage>356</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">22510831</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>de Azevedo</surname>
              <given-names>KML</given-names>
            </name>
            <name>
              <surname>Set&#xFA;bal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Camacho</surname>
              <given-names>LAB</given-names>
            </name>
            <name>
              <surname>Velarde</surname>
              <given-names>LGC</given-names>
            </name>
            <name>
              <surname>de Oliveira</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <year>2009</year>
          <article-title>Seroepidemiological study of human parvovirus B19 among
human immunodeficiency virus-infected patients in a middle-sized city in Rio de
Janeiro, Brazil</article-title>
          <source>Mem Inst Oswaldo Cruz</source>
          <volume>104</volume>
          <fpage>901</fpage>
          <lpage>904</lpage>
          <pub-id pub-id-type="pmid">19876564</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Durigon</surname>
              <given-names>EL</given-names>
            </name>
            <name>
              <surname>Erdman</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Gary</surname>
              <given-names>WG</given-names>
            </name>
            <name>
              <surname>Pallansh</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Torok</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>LJ</given-names>
            </name>
          </person-group>
          <year>1993</year>
          <article-title>Multiple prime pairs for polymerase chain reaction (PCR)
amplification of human parvovirus B19 DNA</article-title>
          <source>J Virol Methods</source>
          <volume>44</volume>
          <fpage>155</fpage>
          <lpage>165</lpage>
          <pub-id pub-id-type="pmid">8263112</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <element-citation publication-type="book">
          <person-group>
            <name>
              <surname>Fauquet</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Mayo</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Maniloff</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Desselberger</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Ball</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <year>2005</year>
          <source>Virus taxonomy: VIIIth report of the ICTV</source>
          <publisher-name>Elsevier/Academic Press</publisher-name>
          <publisher-loc>London</publisher-loc>
          <size units="pages">1162</size>
        </element-citation>
      </ref>
      <ref id="B8">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Ferry</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hirschel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Meylan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Delhumeau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Rauch</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Elzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bernasconi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schimid</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Calmy</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <year>2009</year>
          <article-title>Infrequent replication of parvovirus B19 and
erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic
anemia</article-title>
          <source>Clin Inf Dis</source>
          <volume>50</volume>
          <fpage>115</fpage>
          <lpage>118</lpage>
        </element-citation>
      </ref>
      <ref id="B9">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Freitas</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Romano</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Freitas</surname>
              <given-names>MRC</given-names>
            </name>
            <name>
              <surname>Macedo</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Linhares</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Zanotto</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Durigon</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <year>2008</year>
          <article-title>Molecular characterization of human erythrovirus strains
obtained from patients with several clinical presentations in the Amazon Region of
Brazil</article-title>
          <source>J Clin Virol</source>
          <volume>43</volume>
          <fpage>60</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">18502682</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Frickhofen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <year>1990</year>
          <article-title>Polymerase chain reaction for detection of parvovirus
B19 in immunodeficient patients with anaemia</article-title>
          <source>Behring Inst Mitt</source>
          <volume>85</volume>
          <fpage>46</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="pmid">2171485</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Frickhofen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Abkowitz</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Safford</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Berry</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Antunez-de-Mayolo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Astrow</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Halperin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mintzer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <year>1990</year>
          <article-title>Persistent B19 parvovirus infection in patients infected
with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in
AIDS</article-title>
          <source>Ann Int Med</source>
          <volume>113</volume>
          <fpage>926</fpage>
          <lpage>933</lpage>
          <pub-id pub-id-type="pmid">2173460</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <element-citation publication-type="book">
          <person-group>
            <name>
              <surname>Garcia</surname>
              <given-names>SO</given-names>
            </name>
          </person-group>
          <year>2010</year>
          <source xml:lang="pt">O significado das variantes de eritrovirus em pacientes com
citopenias de origem desconhecida MsC Thesis</source>
          <publisher-name>Universidade de S&#xE3;o Paulo</publisher-name>
          <publisher-loc>S&#xE3;o Paulo</publisher-loc>
          <size units="pages">169</size>
        </element-citation>
      </ref>
      <ref id="B13">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Gyllensten</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sonnerborg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jorup-Ronstrom</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Halvarsson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yun</surname>
              <given-names>Z</given-names>
            </name>
          </person-group>
          <year>1994</year>
          <article-title>Parvovirus B19 infection in HIV-1 infected patients with
anemia</article-title>
          <source>Infection</source>
          <volume>22</volume>
          <fpage>356</fpage>
          <lpage>358</lpage>
          <pub-id pub-id-type="pmid">7843816</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <element-citation publication-type="web">
          <person-group>
            <name>
              <surname>Hall</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <year>1999</year>
          <source xml:lang="pt">BioEdit: biological sequence alignment editor for
Windows</source>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="mbio.ncsu.edu/BioEdit/bioedit.html">mbio.ncsu. edu/BioEdit/bioedit.html</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B15">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Hitzler</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Runkel</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <year>2002</year>
          <article-title>Prevalence of human parvovirus B19 in blood donors as
determined by a haemagglutination assay and verified by the polymerase chain
reaction</article-title>
          <source>Vox Sang</source>
          <volume>82</volume>
          <fpage>18</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">11856463</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Keller</surname>
              <given-names>LW</given-names>
            </name>
            <name>
              <surname>Barbosa</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Melo</surname>
              <given-names>FL</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Neto</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Lanhez</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Durigon</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <year>2009</year>
          <article-title>Phylogenetic analysis of a near-full-length sequence of
an erythrovirus genotype 3 strain isolated in Brazil</article-title>
          <source>Arch Virol</source>
          <volume>154</volume>
          <fpage>1685</fpage>
          <lpage>1687</lpage>
          <pub-id pub-id-type="pmid">19701602</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Koduri</surname>
            </name>
          </person-group>
          <year>2000</year>
          <article-title>Parvovirus B19-related anaemia in HIV-infected
patients</article-title>
          <source>AIDS Patient Care STDS</source>
          <volume>14</volume>
          <fpage>7</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="pmid">12240888</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Kurtzman</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Field</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Oseas</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Blaese</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <year>1989a</year>
          <article-title>Immune response to B19 parvovirus and an antibody defect
in persistent viral infection</article-title>
          <source>J Clin Invest</source>
          <volume>84</volume>
          <fpage>1114</fpage>
          <lpage>1123</lpage>
          <pub-id pub-id-type="pmid">2551923</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Kurtzman</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Frickhofen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kimball</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Nienhuis</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <year>1989b</year>
          <article-title>Pure red-cell aplasia of 10 years&#x2019; duration due to
persistent parvovirus B19 infection and its cure with immunoglobulin
therapy</article-title>
          <source>N Engl J Med</source>
          <volume>321</volume>
          <fpage>519</fpage>
          <lpage>523</lpage>
          <pub-id pub-id-type="pmid">2548098</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Miao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ke</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <year>2012</year>
          <article-title>Human immunodeficiency virus/human parvovirus B19
co-infection in blood donors and AIDS patients in Sichuan, China</article-title>
          <source>Blood Transfus</source>
          <volume>10</volume>
          <fpage>502</fpage>
          <lpage>514</lpage>
          <pub-id pub-id-type="pmid">22790259</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Mylonakis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dickinson</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Mileno</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Flanigan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schiffman</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Mega</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rich</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <year>1999</year>
          <article-title>Persistent parvovirus related anaemia of seven years
duration in a HIV infected patient: complete remission of highly active
antiretroviral therapy</article-title>
          <source>Am J Hem</source>
          <volume>60</volume>
          <fpage>164</fpage>
          <lpage>166</lpage>
        </element-citation>
      </ref>
      <ref id="B22">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Nguyen</surname>
              <given-names>QT</given-names>
            </name>
            <name>
              <surname>Sifer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Allaume</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Servant</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernaudin</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Auguste</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Garbarg-Chenon</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <year>1999</year>
          <article-title>Novel human erythrovirus associated with transient
aplastic anaemia</article-title>
          <source>J Clin Microbiol</source>
          <volume>37</volume>
          <fpage>2483</fpage>
          <lpage>2487</lpage>
          <pub-id pub-id-type="pmid">10405389</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Nguyen</surname>
              <given-names>QT</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Heegaard</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>KE</given-names>
            </name>
          </person-group>
          <year>2002</year>
          <article-title>Identification and a characterization of a second novel
human erythrovirus variant A6</article-title>
          <source>Virology</source>
          <volume>301</volume>
          <fpage>374</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="pmid">12359439</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Oliveira</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Marinho</surname>
              <given-names>TAS</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>ASV</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Faria</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Set&#xFA;bal</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <year>2005</year>
          <article-title xml:lang="pt">Estudo da frequ&#xEA;ncia da infec&#xE7;&#xE3;o pelo parvov&#xED;rus B19 em
casos de doen&#xE7;as exantem&#xE1;ticas no per&#xED;odo de 1994 a 2004</article-title>
          <source>Braz J Infect Dis</source>
          <volume>9</volume>
          <issue>Suppl</issue>
          <fpage>73</fpage>
          <lpage>73</lpage>
        </element-citation>
      </ref>
      <ref id="B25">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Otto</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Vasconcellos</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gomes</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Moreira</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Degrave</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Mendon&#xE7;a-Lima</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Alves-Ferreira</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <year>2008</year>
          <article-title>Chormapipe: a pipeline for analysis, quality control and
management for a DNA sequencing facility</article-title>
          <source>Gen Mol Res</source>
          <volume>7</volume>
          <fpage>861</fpage>
          <lpage>871</lpage>
        </element-citation>
      </ref>
      <ref id="B26">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Pereira</surname>
              <given-names>RFA</given-names>
            </name>
            <name>
              <surname>Cubel Garcia</surname>
              <given-names>RCN</given-names>
            </name>
            <name>
              <surname>Azevedo</surname>
              <given-names>KLM</given-names>
            </name>
            <name>
              <surname>Set&#xFA;bal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Siqueira</surname>
              <given-names>MAMT</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>TX</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>SA</given-names>
            </name>
          </person-group>
          <year>2012</year>
          <article-title>Molecular characterization of human parvovirus B19
strains circulating in Niter&#xF3;i/RJ - Brazil</article-title>
          <source>Virus Reviews &amp; Research</source>
          <volume>17</volume>
          <issue>Suppl</issue>
          <fpage>158</fpage>
          <lpage>159</lpage>
        </element-citation>
      </ref>
      <ref id="B27">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Sanabani</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kleine</surname>
              <given-names>W</given-names>
              <suffix>Neto</suffix>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sabino</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <year>2006</year>
          <article-title>Sequence variability of human erythroviruses present in
bone marrow of Brazilian patients with various B19-related hematological
symptoms</article-title>
          <source>J Clin Microbiol</source>
          <volume>44</volume>
          <fpage>604</fpage>
          <lpage>606</lpage>
          <pub-id pub-id-type="pmid">16455922</pub-id>
        </element-citation>
      </ref>
      <ref id="B28">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Servant</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Laperche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lallemand</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Marinho</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>de SaintMaur</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Meritet</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Garbarg-Chenon</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <year>2002</year>
          <source>J Virol</source>
          <volume>76</volume>
          <fpage>9124</fpage>
          <lpage>9134</lpage>
          <pub-id pub-id-type="pmid">12186896</pub-id>
        </element-citation>
      </ref>
      <ref id="B29">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Servant-Delmas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lefrere</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Morinet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pillet</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <year>2010</year>
          <article-title>Advances in human B19 virus biology</article-title>
          <source>J Virol</source>
          <volume>84</volume>
          <fpage>9658</fpage>
          <lpage>9665</lpage>
          <pub-id pub-id-type="pmid">20631151</pub-id>
        </element-citation>
      </ref>
      <ref id="B30">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>van Elsacker-Niele</surname>
              <given-names>AMW</given-names>
            </name>
            <name>
              <surname>Kroon</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>van der Ende</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Salimans</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Spaan</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Kroes</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <year>1996</year>
          <article-title>Prevalence of parvovirus B19 infection in patients
infected with human immunodeficiency virus</article-title>
          <source>Clin Infect Dis</source>
          <volume>23</volume>
          <fpage>1255</fpage>
          <lpage>1260</lpage>
          <pub-id pub-id-type="pmid">8953068</pub-id>
        </element-citation>
      </ref>
      <ref id="B31">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Ware</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <year>2001</year>
          <article-title>Resolution of chronic parvovirus B19-induced anaemia by
use of highly active antiretroviral therapy in a patient with acquired
immunodeficiency syndrome</article-title>
          <source>Clin Infect Dis</source>
          <volume>32</volume>
          <fpage>122</fpage>
          <lpage>123</lpage>
        </element-citation>
      </ref>
      <ref id="B32">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Weiland</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Salimans</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Fibbe</surname>
              <given-names>WE</given-names>
            </name>
            <name>
              <surname>Kluin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <year>1989</year>
          <article-title>Prolonged parvovirus B19 infection with severe anaemia
in a bone marrow transplant patient</article-title>
          <source>Br J Haematol</source>
          <volume>71</volume>
          <size units="pages">300</size>
        </element-citation>
      </ref>
      <ref id="B33">
        <element-citation publication-type="web">
          <person-group>
            <collab>WHO - World Health Organization</collab>
          </person-group>
          <year>2001</year>
          <source>Iron deficiency anaemia. Assessment, prevention and control. A
guide for programme managers</source>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf">who.int/nutrition/publications/en/ida_assessment_prevention_control.pdf</ext-link>
          </comment>
        </element-citation>
      </ref>
      <ref id="B34">
        <element-citation publication-type="journal">
          <person-group>
            <name>
              <surname>Woolf</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Campion</surname>
              <given-names>GV</given-names>
            </name>
            <name>
              <surname>Chishick</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wise</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cohen</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Klouda</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Caul</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Dieppe</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <year>1989</year>
          <article-title>Clinical manifestations of human parvovirus B19 in
adults</article-title>
          <source>Arch Intern Med</source>
          <volume>149</volume>
          <fpage>1153</fpage>
          <lpage>1156</lpage>
          <pub-id pub-id-type="pmid">2541666</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
